These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34626144)

  • 1. Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.
    Ishigooka J; Nakagome K; Ohmori T; Iwata N; Inada K; Iga JI; Kishi T; Fujita K; Kikuchi Y; Shichijo T; Tabuse H; Koretsune S; Terada H; Terada H; Kishimoto T; Tsutsumi Y; Kanda Y; Ohi K; Sekiyama K
    Psychiatry Clin Neurosci; 2022 Jan; 76(1):22-31. PubMed ID: 34626144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.
    Ishigooka J; Nakagome K; Ohmori T; Iwata N
    BMC Psychiatry; 2013 Oct; 13():243. PubMed ID: 24090047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
    Bervoets C; Morrens M; Vansteelandt K; Kok F; de Patoul A; Halkin V; Pitsi D; Constant E; Peuskens J; Sabbe B
    CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
    Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
    Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
    Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
    CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
    Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
    Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
    Weiden PJ; Du Y; Liu CC; Stanford AD
    CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.
    Huang MW; Yang TT; Ten PR; Su PW; Wu BJ; Chan CH; Lan TH; Liu IC; Chiu WC; Li CY; Cheng KS; Yeh YC
    BMC Clin Pharmacol; 2012 Jan; 12():1. PubMed ID: 22225965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 13. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations.
    Anderson JP; Icten Z; Alas V; Benson C; Joshi K
    BMC Psychiatry; 2017 Oct; 17(1):346. PubMed ID: 29047368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
    Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
    Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
    Winter-van Rossum I; Weiser M; Galderisi S; Leucht S; Bitter I; Glenthøj B; Hasan A; Luykx J; Kupchik M; Psota G; Rocca P; Stefanis N; Teitelbaum A; Bar Haim M; Leucht C; Kemmler G; Schurr T; ; Davidson M; Kahn RS; Fleischhacker WW
    Lancet Psychiatry; 2023 Mar; 10(3):197-208. PubMed ID: 36716759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
    Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
    J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
    Ninomiya Y; Miyamoto S; Tenjin T; Ogino S; Miyake N; Kaneda Y; Sumiyoshi T; Yamaguchi N
    Psychiatry Clin Neurosci; 2014 Dec; 68(12):841-849. PubMed ID: 24835911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jun; 138():444-452. PubMed ID: 33964682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.